Excision Medical

Excision Medical is a private, pre-revenue medical device company founded in 2012 and based in Austin, Texas. It is developing two novel catheter-based platforms: a septal myotomy device for hypertrophic cardiomyopathy and a leaflet modification tool for patients undergoing TAVR who are at risk of coronary obstruction. The company is led by a seasoned team with a track record of successful medical device ventures and acquisitions, positioning it to address significant unmet needs in the structural heart space.

Catheter-based platforms for transcatheter intracardiac tissue modification. Includes a septal myotomy device for laceration of hypertrophied heart muscle and an RF-enabled leaflet modification tool for precise cutting of aortic valve leaflets. Both utilize transfemoral access and emphasize control, safety, and repeatability.

In HCM, competition includes surgical myectomy (gold standard), alcohol septal ablation, and pharmaceuticals. Other companies are exploring transcatheter devices for septal reduction. In the TAVR space, competition is indirect, focusing on valve designs that aim to minimize coronary obstruction. Excision's novel approach to leaflet modification is a first-of-its-kind solution to a specific TAVR complication.